Treatment of Anogenital Papillomavirus Infections with an Acyclic Nucleoside Phosphonate Analogue
- 5 October 1995
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 333 (14) , 943-944
- https://doi.org/10.1056/nejm199510053331418
Abstract
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) is an acyclic nucleoside phosphonate analogue with broad-spectrum antiviral activity against DNA viruses, including herpesviruses (herpes simplex virus, varicella–zoster virus, cytomegalovirus, and Epstein–Barr virus), adenoviruses, poxviruses, and papillomaviruses.1,2 We recently showed that local injections of HPMPC into a life-threatening squamous papilloma of the hypopharynx–esophagus eradicated the tumor.2 Two years later, the patient was still free of disease. We report the use of HPMPC in three patients with AIDS and severe, relapsing anogenital human papillomavirus lesions.This publication has 4 references indexed in Scilit:
- Successful treatment of a squamous papilloma of the hypopharynx‐esophagus by local injections of (S)‐1‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)cytosineJournal of Medical Virology, 1995
- Major Therapeutic Uses of InterferonsClinical Immunotherapeutics, 1995
- Treatment of Papillomavirus Infections: Recent Practice and Future ApproachesIntervirology, 1994
- Therapeutic potential of HPMPC as an antiviral drugReviews in Medical Virology, 1993